{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:54:37Z","timestamp":1789786477897,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wellcome Trust (GB)","award":["095317\/Z\/11\/Z"],"award-info":[{"award-number":["095317\/Z\/11\/Z"]}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["103838"],"award-info":[{"award-number":["103838"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00415-017-8647-0","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T06:25:42Z","timestamp":1508999142000},"page":"2457-2463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington\u2019s disease"],"prefix":"10.1007","volume":"264","author":[{"given":"Benjamin R.","family":"Underwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyn W.","family":"Green-Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley E.","family":"Lazic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Rubinsztein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"8647_CR1","volume-title":"Huntington\u2019s disease, Oxford monographs in medical genetics","author":"GP Bates","year":"2014","unstructured":"Bates GP, Tabrizi SJ, Jones L (2014) Huntington\u2019s disease, Oxford monographs in medical genetics, 4th edn. Oxford University Press, Oxford","edition":"4"},{"issue":"1","key":"8647_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1517\/14656566.2016.1109630","volume":"17","author":"SL Mason","year":"2016","unstructured":"Mason SL, Barker RA (2016) Advancing pharmacotherapy for treating Huntington\u2019s disease: a review of the existing literature. Expert Opin Pharmacother 17(1):41\u201352","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"8647_CR3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"SE Andrew","year":"1993","unstructured":"Andrew SE et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat Genet 4(4):398\u2013403","journal-title":"Nat Genet"},{"issue":"5\u20136","key":"8647_CR4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.mam.2006.08.008","volume":"27","author":"B Ravikumar","year":"2006","unstructured":"Ravikumar B, Rubinsztein DC (2006) Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? Mol Aspects Med 27(5\u20136):520\u2013527","journal-title":"Mol Aspects Med"},{"issue":"3","key":"8647_CR5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/hmg\/ddi458","volume":"15","author":"Z Berger","year":"2006","unstructured":"Berger Z et al (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15(3):433\u2013442","journal-title":"Hum Mol Genet"},{"issue":"15","key":"8647_CR6","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1074\/jbc.R109.072181","volume":"285","author":"M Renna","year":"2010","unstructured":"Renna M et al (2010) Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem 285(15):11061\u201311067","journal-title":"J Biol Chem"},{"issue":"11","key":"8647_CR7","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/hmg\/ddq093","volume":"19","author":"C Rose","year":"2010","unstructured":"Rose C et al (2010) Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington\u2019s disease. Hum Mol Genet 19(11):2144\u20132153","journal-title":"Hum Mol Genet"},{"issue":"2","key":"8647_CR8","doi-asserted-by":"crossref","first-page":"e29522","DOI":"10.1371\/journal.pone.0029522","volume":"7","author":"Huntington Study Group","year":"2012","unstructured":"Huntington Study Group (2012) C.I. and E. Dorsey, Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS One 7(2):e29522","journal-title":"PLoS One"},{"issue":"1","key":"8647_CR9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","volume":"10","author":"SJ Tabrizi","year":"2011","unstructured":"Tabrizi SJ et al (2011) Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10(1):31\u201342","journal-title":"Lancet Neurol"},{"issue":"24","key":"8647_CR10","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1212\/WNL.0b013e3182020123","volume":"75","author":"N Bechtel","year":"2010","unstructured":"Bechtel N et al (2010) Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 75(24):2150\u20132160","journal-title":"Neurology"},{"issue":"1","key":"8647_CR11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24\u00a0month observational data. Lancet Neurol 11(1):42\u201353","journal-title":"Lancet Neurol"},{"issue":"7","key":"8647_CR12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12(7):637\u2013649","journal-title":"Lancet Neurol"},{"issue":"1","key":"8647_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29(1):1\u20133","journal-title":"Neurology"},{"issue":"9","key":"8647_CR14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0895-4356(94)90122-8","volume":"47","author":"WA Kukull","year":"1994","unstructured":"Kukull WA et al (1994) The Mini-Mental State Examination score and the clinical diagnosis of dementia. J Clin Epidemiol 47(9):1061\u20131067","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"8647_CR15","first-page":"266","volume":"5","author":"TW Robbins","year":"1994","unstructured":"Robbins TW et al (1994) Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5(5):266\u2013281","journal-title":"Dementia"},{"key":"8647_CR16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/brain\/awl027","volume":"129","author":"BR Underwood","year":"2006","unstructured":"Underwood BR et al (2006) Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129:877\u2013886","journal-title":"Brain"},{"key":"8647_CR17","unstructured":"Stan Development Team (2016) RStan: the R interface to Stan, Version 2.9.0. \n                        http:\/\/mc-stan.org\/"},{"key":"8647_CR18","unstructured":"Stan Development Team (2016) Stan modeling language users guide and reference manual, version 2.9.0. \n                        http:\/\/mc-stan.org"},{"key":"8647_CR19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2013.123","volume":"70","author":"ER Dorsey","year":"2013","unstructured":"Dorsey ER et al (2013) Natural history of huntington disease. JAMA Neurol 70:1520\u20131530","journal-title":"JAMA Neurol"},{"issue":"2","key":"8647_CR20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","volume":"54","author":"K Marder","year":"2000","unstructured":"Marder K et al (2000) Rate of functional decline in Huntington\u2019s disease. Huntington Study Group. Neurology 54(2):452\u2013458","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-017-8647-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8647-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8647-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T05:31:30Z","timestamp":1510723890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-017-8647-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["8647"],"URL":"https:\/\/doi.org\/10.1007\/s00415-017-8647-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}